Meropenem is a broad-spectrum carbapenem antibiotic given by injection. Reserved for serious and life-threatening infections in hospital and intensive care settings when first- and second-line antibiotics have failed or when the organism is resistant. It is listed on the WHO Model List of Essential Medicines as a critical-tier antibiotic subject to strict stewardship protocols.

Meropenem as a Carbapenem - Drug Class Explained

Carbapenems are the broadest-spectrum beta-lactam antibiotics; their modified ring system confers resistance to most beta-lactamase enzymes. Meropenem, imipenem-cilastatin, ertapenem and doripenem are the principal clinical members. They are effective against the vast majority of Gram-positive and Gram-negative bacteria including those producing ESBLs and AmpC beta-lactamases.

Meropenem is often reserved as a last-resort antibiotic for treating severe or life threatening bacterial infections especially those caused by multidrug-resistant bacteria. Using it carefully helps slow the development of antibiotic resistance and preserves its effectiveness for patients who need it most.

Why Meropenem Is Used Only in Hospitals

Meropenem has no oral formulation and it is unstable at gastric pH and not absorbed from the GI tract. Intravenous infusion is the standard route typically over 15 to 30 minutes for standard dosing or three to four hours for extended infusions in pharmacodynamic optimisation against resistant organisms.

The infections requiring meropenem are septicaemia, nosocomial pneumonia, meningitis, and febrile neutropenia - all requiring close monitoring, laboratory support and multidisciplinary management, which are only feasible in hospital. OPAT with meropenem is not standard practice in India.

Infections Treated with Meropenem Injection

Common infections treated are:

• Hospital-acquired and ventilator-associated pneumonia: Particularly caused by MDR Gram-negative organisms including Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii

• Complicated intra-abdominal infections: Peritonitis, abdominal abscess and post surgical sepsis requiring broad anaerobic and Gram-negative cover

• Complicated urinary tract infections: Pyelonephritis and urosepsis from ESBL-producing organisms unresponsive to cephalosporins

• Bacterial meningitis: Good CSF penetration; used when resistant Gram-negative organisms are causative or suspected

• Febrile neutropenia: In immunocompromised patients including those on chemotherapy, where broad-spectrum empirical cover is necessary

• Septicaemia: Bloodstream infections with unknown or resistant organisms in critically ill patients

• Skin and soft tissue infections: Necrotising fasciitis and severe diabetic foot infections with mixed Gram-negative flora.

How Meropenem Works Against Bacteria

Meropenem is bactericidal. It binds to penicillin binding proteins (PBPs), blocking the final cross-linking steps of peptidoglycan synthesis and causing the cell wall to fail to form. The bacterium then lyses under its own osmotic pressure. Meropenem has high affinity for PBP2 and PBP3 in Gram-negative organisms this explains its potency against these pathogens.

Meropenem is effective against many bacteria that are resistant to other antibiotics because it can withstand most bacterial enzymes that normally destroy antibiotics. However some highly resistant bacteria produce special enzymes such as NDM-1 that can break down meropenem and make it ineffective. This is one reason why meropenem is reserved for serious infections.

How It Is Given and in What Doses

• Standard adult dosing: 500mg to 1g IV every eight hours; 1g every eight hours for severe infections including meningitis, febrile neutropenia and Pseudomonas. 

• Paediatric: 10 to 20mg/kg every eight hours; 40mg/kg every eight hours for meningitis. 

• Neonatal: 20mg/kg every 12 hours (term) or 20mg/kg every 24 hours (preterm). 

Side Effects of Meropenem Injection

Common adverse effects are: 

• Nausea

• Vomiting

• Diarrhoea

• Elevated liver enzymes 

• Injection site reactions including pain and thrombophlebitis

• Headache 

• Rash.

Serious adverse effects: 

• Clostridioides difficile-associated diarrhoea 

• Hypersensitivity reactions 

• Seizures

• Thrombocytosis and leukopenia may occur with prolonged use.

Who Should Not Receive Meropenem?

Certain group of people should avoid meropenem:

• Known hypersensitivity to meropenem or any carbapenem

• Severe immediate hypersensitivity to penicillin or other beta-lactams

• Severe renal impairment 

• Pregnancy (classified as Pregnancy Category B)

• Concurrent valproate therapy as meropenem significantly reduces valproate plasma levels and can precipitate breakthrough seizures; this combination should be avoided unless seizures can be managed by alternative agents.

Drug Interactions and Precautions

The most clinically critical interaction is with valproic acid. Meropenem reduces valproate plasma concentrations (by 60 to 100% within 48 hours) precipitating breakthrough seizures in epilepsy patients. Valproate dose adjustment does not prevent the interaction. Other interactions are:

• Probenecid 

• Nephrotoxic agents like aminoglycosides, vancomycin and amphotericin B

• Colistin.

Antibiotic Resistance and Why Meropenem Is a Last Resort

Carbapenems are the last widely available antibiotic class effective against multidrug resistant Gram-negative bacteria. When carbapenem resistance develops, remaining options are fewer, more toxic, less available and substantially more expensive.

Meropenem vs Imipenem vs Ertapenem: Key Differences

Meropenem and imipenem-cilastatin have broadly similar spectra. Imipenem requires cilastatin to prevent renal metabolism by dehydropeptidase-1 - meropenem is stable to this enzyme and needs no addition. Imipenem carries a higher seizure risk, making meropenem preferred when CNS infection or seizure risk is a concern. Meropenem has superior activity against Pseudomonas aeruginosa.

Ertapenem lacks activity against Pseudomonas aeruginosa and Acinetobacter baumannii - clinically useful as it treats ESBL infections without selecting for Pseudomonas resistance and can be given once daily, making it suitable for outpatient parenteral therapy. Doripenem has a comparable spectrum; its use is less widespread in India.

FAQs

1. Why is meropenem only given by injection and not as a tablet?

   Meropenem is unstable at gastric pH & destroyed in the GI tract before absorption. IV administration is the only route that achieves the plasma and tissue concentrations required for efficacy against serious infections.

2. What types of serious infections need meropenem?

   Infections treated are hospital-acquired and ventilator-associated pneumonia, bloodstream infections, complicated intra-abdominal infections, meningitis caused by resistant Gram-negative organisms, febrile neutropenia, and severe necrotising or diabetic foot infections.

3. Is meropenem a last-resort antibiotic?

   Yes meropenem is reserved for infections caused by multidrug-resistant organisms unresponsive to other antibiotics or when culture data indicates only a carbapenem will be effective. Using it where narrower-spectrum agents would suffice accelerates resistance and depletes a critical resource.

4. How long does a course of meropenem injection usually last?

   Duration depends on infection type: 

   • Intra-abdominal infections 5 to 7 days

   • Hospital-acquired pneumonia 7 to 8 days

   • Meningitis 7 to 14 days

   • Febrile neutropenia until neutrophil recovery

   • Bacteraemia 7 to 14 days. 

   Clinical response, culture data and procalcitonin trends guide duration.

5. Can meropenem cause seizures?

   Yes though less frequently than with imipenem-cilastatin. Risk is higher with pre-existing CNS disease, renal impairment or high doses. Concurrent valproate therapy reduces valproate to subtherapeutic levels. Any new neurological symptoms during treatment require immediate assessment.

6. Is meropenem safe for newborns and children?

   Yes with weight- and age-based dosing. Meropenem is authorised in children above three months and used in neonatal ICUs for neonatal sepsis, meningitis and complicated infections as neonatal dosing accounts for immature renal function and slower clearance.

7. What bacteria is meropenem most effective against?

   Meropenem is effective against Klebsiella pneumoniae (including ESBL-producing strains), Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, Enterobacter species, Haemophilus influenzae, Streptococcus species and many Staphylococcus species (not MRSA). Anaerobic coverage is broad. It is not effective against NDM-1 or other metallo-beta-lactamase-producing organisms.

8. Why is meropenem given in an ICU rather than at home?

   ICU administration allows continuous IV access, close observation for seizures and allergic reactions, renal function monitoring and reassessment to de-escalate as culture results arrive. The infections that warrant meropenem are inherently unstable and home administration is not safe.

9. Can meropenem cause an allergic reaction?

   Yes in less than 1% of patients, ranging from mild rash to anaphylaxis. Prior penicillin allergy confers cross-reactivity risk. A detailed allergy history must be taken before administration. Anaphylaxis requires immediate drug cessation, adrenaline and emergency care.

10. Is meropenem related to penicillin?

    Meropenem shares the beta-lactam ring with penicillins and cephalosporins, though the carbapenem ring is structurally distinct. Cross-reactivity in penicillin-allergic patients is possible but occurs at lower rates than penicillin-cephalosporin cross-reactivity. Patients with confirmed severe penicillin anaphylaxis should only receive meropenem when no alternative exists.

References

1. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027–52. https://doi.org/10.2165/00003495-200767070-00006

2. Patel G, Bonomo RA. 'Stormy waters ahead': global emergence of carbapenemases. Front Microbiol. 2013;4:48. https://doi.org/10.3389/fmicb.2013.00048

3. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum beta-lactamase producing Enterobacterales, carbapenem-resistant Enterobacterales, and Pseudomonas aeruginosa. Clin Infect Dis. 2022;75(2):187–212. https://doi.org/10.1093/cid/ciac268

4. ICMR — National Centre for Disease Control. Antimicrobial resistance surveillance network annual report 2022. New Delhi: ICMR; 2022. 

   https://www.icmr.gov.in/ctemp/amr_report.html

5. Kuczkowski A, Kmiecik J, Sobieralski K. Meropenem's effect on valproic acid plasma concentration: case report and review of the literature. Clin Exp Pharmacol Physiol. 2020;47(9):1612–6. https://doi.org/10.1111/1440-1681.13334